Hey Raki,
With a happy New Year to all long term IMU investors, plus cancer sufferers and their loved ones.
Whilst taking a break from posting, I've still dropped in each day in keeping up with everything IMU.
Firstly, to those non holding sceptics of IMU. We thank you for your voiced concerns over our investments. Many draw comparison's and hold shares in other oncology stocks. Life's about choices, with many here having made an educated choice over the price and quantity, they've paid for holding IMU. Whilst I support constructive criticism of any stock, should you never have anything positive to say and don't hold any IMU - then please just leave us all alone. Your motives are only seen here as being down rampers, or those who need to find some interest's more in line with their lives.
Capital Raising was the hot topic leading into Christmas, having only 2/3 quarters funded ( after Government refunds). Well that was put to bed just prior to Christmas. It brings both a positive's and negative's, for mine.
Firstly it wasn't as destructive, with dilution (Shares being printed off in devaluing those already held) as many feared. Considering there was a market cap of around $300m comprising approximately 8 billion shares and options being held prior. A $20m raise via convertible notes plus options comprising roughly 500m additional shares, sees dilution of only 1/16th or 6.5%. This comes with $20m up front (an additional quarter's funding) with a potential additional $25m in years to come, should the options be exercised. That changes IMU's capital reserves to comprise up to one years funding.
The capital raise of that amount and nature, both excites and scares me equally. Firstly, why would you even bother raising just $20m (1 quarter) in funding should any deals or data be about to drop, creating a rerate (boom) in the share price. It could be argued that ASX rules require each stock to hold two quarters of funding, coupled with only being able to print off 10% in new shares in a 12 month period. It had been over 15 months since the previous,
so it might have just been done in keeping everything shipshape financially until mid 2025.
Alternatively, if they foresee something game changing happening in early 2025 then $20m might be all they needed. For mine, transparency and an update on the direction of IMU is imperative by IMU management- Pronto !
The expansions of studies and treatments only adds to our expectations of successful results. Whilst we've all been educated in the time required, involving such studies- it's now been over 14 months since any updates with the crucial Mast study, in particular. The management led by Leslie, really need to throw investors a bone. Transparency and direction, have always been my gripe with IMU. Should she come out talking up prospects, without anything to report, then I'd suggest her days and our investment's future is numbered. I can't recall in over 38 years of investing, any other CEO that's needed to choose her words and communications more carefully. Leslie has filled her pockets and secured her position for another year. Investors however, are still witnessing over three years of decimated share prices, despite all of Leslie's hype and constant suggestions of prosperity.
This is sink or swim time for IMU, over the next six months. Data, although being pushed back twice now over almost a year, will not only be imminent- but demanded very soon by IMU investors.
Like many, I'm all in !
This is based on my confidence in Yuman Fong, coupled with the rare feedback we receive surrounding successful data. For mine, by mid 2025 the IMU share price will be trading 5-10 times than at present, or be sold off in a fire sale. Hard news, but the up side seems more likely to me, coupled with the share price trading so low now, that things can only get better !
A huge year for IMU coming up - hang in there !
Fingers crossed for all long term investors, and cancer sufferers.
-GO IMU!
Not Financial Advice - Opinions Only - DYOR!
Expand
(20min delay)